SCHEMBL6430815

SCHEMBL6430815

NC(=O)Cn1nc(-c2ccc(NS(=O)(=O)c3cccc(Cl)c3Cl)c(F)c2)c2c(N)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR4 P51679 6/20 0.57
▸ PIK3CD O00329 2/20 0.54
▸ PIK3CA P42336 2/20 0.54
▸ PIK3CB P42338 2/20 0.54
▸ PIK3CG P48736 2/20 0.54
▸ PRKDC P78527 2/20 0.54
▸ SGK1 O00141 2/20 0.48
▸ KIT P10721 2/20 0.46
▸ RIPK1 Q13546 2/20 0.43
▸ ACLY P53396 1/20 0.41
▸ PTGES2 Q9H7Z7 1/20 0.40
▸ TGFBR1 P36897 1/20 0.40
▸ EIF2AK3 Q9NZJ5 1/20 0.40
▸ ABL1 P00519 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ HCK P08631 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ EPHB4 P54760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433439 0.94 CCR4 (0.55) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5804448 0.92 CCR4 (0.53) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5805254 0.92 CCR4 (0.47) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6430931 0.90 SGK1 (0.48) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5803133 0.90 CCR4 (0.49) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6431769 0.88 CCR4 (0.46) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6433848 0.88 CCR4 (0.44) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6433539 0.87 CCR4 (0.46) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5823633 0.87 CCR4 (0.46) CCR4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL6433271 0.87 CCR4 (0.47) CCR4PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN CCR4 271/4885PIK3CD 470/4885PIK3CA 625/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 CCR4 2434/4885PIK3CD 1497/4885PIK3CA 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback